Related references
Note: Only part of the references are listed.Analysis of online plan adaptation for 1.5T magnetic resonance-guided stereotactic body radiotherapy (MRgSBRT) of prostate cancer
Darren M. C. Poon et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)
Online adaptive radiotherapy potentially reduces toxicity for high-risk prostate cancer treatment
Rasmus Lubeck Christiansen et al.
RADIOTHERAPY AND ONCOLOGY (2022)
A narrative review of MRI acquisition for MR-guided-radiotherapy in prostate cancer
Jing Yuan et al.
QUANTITATIVE IMAGING IN MEDICINE AND SURGERY (2022)
Gantry-Based 5-Fraction Elective Nodal Irradiation in Unfavorable-Risk Prostate Cancer: Outcomes From 2 Prospective Studies Comparing SABR Boost With MR Dose-Painted HDR Brachytherapy Boost
Hima Bindu Musunuru et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)
NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer
William A. Hall et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)
Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients
Ritchell van Dams et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)
Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial
Linda G. W. Kerkmeijer et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial
Vedang Murthy et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC) : patient-reported quality-of-life outcomes of a randomised, controlled, 3 trial
Per Fransson et al.
LANCET ONCOLOGY (2021)
Elective Nodal Radiotherapy for Prostate Cancer: For None, Some, or all?
Nicholas G. Zaorsky et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
Nicolas Mottet et al.
EUROPEAN UROLOGY (2021)
Stereotactic Body Radiotherapy for High-Risk Prostate Cancer: A Systematic Review
Robert Foerster et al.
CANCERS (2021)
1.5T Magnetic Resonance-Guided Stereotactic Body Radiotherapy for Localized Prostate Cancer: Preliminary Clinical Results of Clinician- and Patient-Reported Outcomes
Darren M. C. Poon et al.
CANCERS (2021)
Elective nodal radiotherapy in prostate cancer
Gert De Meerleer et al.
LANCET ONCOLOGY (2021)
Treatment Strategies for High-Risk Localized and Locally Advanced and Oligometastatic Prostate Cancer
Tomoyuki Makino et al.
CANCERS (2021)
Feasibility of MR-guided ultrahypofractionated radiotherapy in 5, 2 or 1 fractions for prostate cancer
Jonathan Mohajer et al.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY (2021)
Stereotactic body radiation therapy use for high risk prostate cancer in the United States
Sagar A. Patel et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2021)
Hyprofractionated Versus Conventionally Fractionated Radiation Therapy for Patients with Intermediate- or High-Risk, Localized, Prostate Cancer: 7-Year Outcomes From the Randomized, Multicenter, Open-Label, Phase 3 HYPRO Trial
Kim C. de Vries et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
Stereotactic body radiotherapy for localized prostate cancer-5-year efficacy results
Kristiina Vuolukka et al.
RADIATION ONCOLOGY (2020)
Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer
Cedric Draulans et al.
RADIOTHERAPY AND ONCOLOGY (2020)
Stereotactic Ablative Body Radiotherapy for Intermediate- or High-Risk Prostate Cancer
Andrew Loblaw
CANCER JOURNAL (2020)
Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline
Scott C. Morgan et al.
JOURNAL OF UROLOGY (2019)
Who Dies From Prostate Cancer? An Analysis of the Surveillance, Epidemiology and End Results Database
S. Roy et al.
CLINICAL ONCOLOGY (2019)
Prostate Cancer, Version 2.2019
James L. Mohler et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Feasibility of stereotactic radiotherapy using a 1.5 T MR-linac: Multi-fraction treatment of pelvic lymph node oligometastases
Anita M. Werensteijn-Honingh et al.
RADIOTHERAPY AND ONCOLOGY (2019)
Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients
Luca Nicosia et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial
Anders Widmark et al.
LANCET (2019)
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial
Douglas H. Brand et al.
LANCET ONCOLOGY (2019)
Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL)
David Dearnaley et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
SABR in High-Risk Prostate Cancer: Outcomes From 2 Prospective Clinical Trials With and Without Elective Nodal Irradiation
Yasir Alayed et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Early Tolerance Outcomes of Stereotactic Hypofractionated Accelerated Radiation Therapy Concomitant with Pelvic Node Irradiation in High-risk Prostate Cancer
Attapol Pinitpatcharalert et al.
ADVANCES IN RADIATION ONCOLOGY (2019)
Adaptive radiotherapy: The Elekta Unity MR-linac concept
Dennis Winkel et al.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY (2019)
Early Results of Extreme Hypofractionation Using Stereotactic Body Radiation Therapy for High-risk, Very High-risk and Node-positive Prostate Cancer
V. Murthy et al.
CLINICAL ONCOLOGY (2018)
Magnetic Resonance Image-Guided Radiotherapy (MRIgRT): A 4.5-Year Clinical Experience
L. E. Henke et al.
CLINICAL ONCOLOGY (2018)
Phase 1-2 Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation in Patients With High-Risk Prostate Cancer (SATURN): Early Toxicity and Quality of Life
Hima Bindu Musunuru et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline
Scott C. Morgan et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial
Mack Roach et al.
LANCET ONCOLOGY (2018)
Elective pelvic nodal radiotherapy: is the jury still out?
Juanita Crook
NATURE REVIEWS UROLOGY (2016)
Is There a Role for Pelvic Irradiation in Localized Prostate Adenocarcinoma? Update of the Long-Term Survival Results of the GETUG-01 Randomized Study
Pascal Pommier et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
David Dearnaley et al.
LANCET ONCOLOGY (2016)
Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study
Steven Joniau et al.
EUROPEAN UROLOGY (2015)
A Phase 1/2 Trial of Brief Androgen Suppression and Stereotactic Radiation Therapy (FASTR) for High- Risk Prostate Cancer
Glenn Bauman et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)
MR guidance in radiotherapy
Jan J. W. Lagendijk et al.
PHYSICS IN MEDICINE AND BIOLOGY (2014)
Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival
Wilma D. Heemsbergen et al.
RADIOTHERAPY AND ONCOLOGY (2014)
Identification of men with the highest risk of early disease recurrence after radical prostatectomy
Debasish Sundi et al.
PROSTATE (2014)
Magnetic Resonance-Guided Adaptive Radiotherapy: A Solution to the Future
Patrick Kupelian et al.
SEMINARS IN RADIATION ONCOLOGY (2014)
Meta-analysis of the Alpha/Beta Ratio for Prostate Cancer in the Presence of an Overall Time Factor: Bad News, Good News, or No News?
Ivan R. Vogelius et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy
Jochen Walz et al.
BJU INTERNATIONAL (2011)
Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial
Padraig Warde et al.
LANCET (2011)
Outcome Predictors of Radical Prostatectomy in Patients With Prostate-Specific Antigen Greater Than 20 ng/ml: A European Multi-Institutional Study of 712 Patients
Martin Spahn et al.
EUROPEAN UROLOGY (2010)
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study
Michel Bolla et al.
LANCET ONCOLOGY (2010)
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial
Anders Widmark et al.
LANCET (2009)
High-risk prostate cancer in the United States, 1990-2007
Matthew R. Cooperberg et al.
WORLD JOURNAL OF UROLOGY (2008)
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial
David P. Dearnaley et al.
LANCET ONCOLOGY (2007)
Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate - A randomized controlled trial
AL Zietman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Is α/β for prostate tumors really low?
J Fowler et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2001)
Share Paper
